New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
10:55 EDTISIS, ARWRArrowhead weakness related to Isis' competing HBV program, says Piper Jaffray
Arrowhead Research (ARWR) shares are lower after competitor ISIS Pharmaceuticals (ISIS) announced preclinical data on its antisense compound targeting hepatitis B virus. Piper anticipates Arrowhead will begin multi-dose ARC-520 Phase II studies in Q4 and reiterates its Overweight rating and $24 price target on Arrowhead.
News For ARWR;ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
11:37 EDTARWROppenheimer reports 5.49% passive stake in Arrowhead
January 23, 2015
08:14 EDTARWRBridger Management reports 5.5% passive stake in Arrowhead
Subscribe for More Information
January 22, 2015
10:03 EDTARWROn the Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTARWROn The Fly: Pre-market Movers
Subscribe for More Information
07:14 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
06:33 EDTARWRArrowhead downgraded to Hold from Buy at Deutsche Bank
Subscribe for More Information
January 15, 2015
05:26 EDTISISIsis receives orphan status for myotonic dystrophy drug treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use